Heritage Investors Management Corp bought a new position in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 74,878 shares of the biotechnology company’s stock, valued at approximately $113,000. Heritage Investors Management Corp owned 0.08% of Pluristem Therapeutics as of its most recent filing with the SEC.
Separately, Jane Street Group LLC boosted its holdings in Pluristem Therapeutics by 62.4% in the 1st quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock worth $134,000 after buying an additional 41,796 shares during the period. 4.54% of the stock is currently owned by institutional investors.
PSTI has been the subject of several recent analyst reports. Seaport Global Securities reaffirmed a “buy” rating and issued a $5.00 target price on shares of Pluristem Therapeutics in a report on Friday, October 6th. Maxim Group reaffirmed a “buy” rating and issued a $2.00 target price on shares of Pluristem Therapeutics in a report on Tuesday, September 5th. HC Wainwright set a $4.00 target price on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 17th. ValuEngine raised shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research downgraded shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $4.38.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Want to see what other hedge funds are holding PSTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pluristem Therapeutics, Inc. (NASDAQ:PSTI).
What are top analysts saying about Pluristem Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pluristem Therapeutics Inc. and related companies.